Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06128200 · ClinicalTrials.gov registry record · NA
NEUROMARK Randomized Controlled Trial
A NA study, sponsored by Neurent Medical.
- Completed
- Registry status
- NA
- Development phase
- 132
- Enrollment target
NCT06128200: Completed NA study, sponsored by Neurent Medical.
NCT06128200 is a NA study that has completed, run by Neurent Medical. The registered enrollment target is 132 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06128200, a NA study, has completed, sponsored by Neurent Medical.
- COMPLETED
- Registry status
- NA
- Development phase
- 132 participants
- Enrollment target
Study Summary
The NEUROMARK RCT Study is a prospective, multicenter, randomized, sham-controlled, single-blinded, superiority trial.
Primary Outcome
Comparison of the percentage of responders (participants with a 30% or greater reduction in rTNSS relative to baseline) between study arms at 90-days
Interventions
- DEVICE NEUROMARK System
- DEVICE Sham NEUROMARK System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 132 participants |
| Start Date | 2023-10-10 |
| Est. Completion | 2025-11-26 |
| Phase | NA |
What the finished NCT06128200 record still lists
NCT06128200 is an interventional study that assigns participants to a tested intervention. The registered 132 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower).
The record links to 0 conditions, and to 2 interventions - of which NEUROMARK System is the first listed.
NCT06128200 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06128200 about?
NCT06128200 is a clinical study titled "NEUROMARK Randomized Controlled Trial". The NEUROMARK RCT Study is a prospective, multicenter, randomized, sham-controlled, single-blinded, superiority trial.
What is the current status of trial NCT06128200?
This trial is currently completed. It is a NA study. The enrollment target is 132 participants. The study started on 2023-10-10. Estimated completion is 2025-11-26.
What interventions are being tested in trial NCT06128200?
The interventions under investigation include: NEUROMARK System (DEVICE), Sham NEUROMARK System (DEVICE).
Who is sponsoring clinical trial NCT06128200?
This trial is sponsored by Neurent Medical, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06128200's enrollment target sits among peer trials
132 729th of 2000 higher than 1,269 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01766297 · 132 participants · Phase 2
Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
- NCT04002947 · 132 participants · Phase 2
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
- NCT04128189 · 132 participants · Phase 3
Shingrix in Renal Transplant Recipients
- NCT04199780 · 132 participants · NA
Effects of tDCS Combined With CBI on Postsurgical Pain
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI